S&P 5007,533.77▼0.5% Nasdaq25,881.95▼1.5% Dow52,552.97▼0.2% Russell 2K2,974.57▼0.1% 10-Yr4.57%+2bp VIX16.73+1.06 WTI$79.00▼0.8% Gold$3,981.40▼1.6% EUR/USD1.145▼0.2% BTC$66,569▲2.0% Nikkei68,752▲1.5%
At close · Thu, Jul 16, 2026
Daily Market Updates.

US Markets

Home›US Markets›M&A & Deals›Novo Nordisk sues Eli Lilly over ads in GLP-1 competit…

Novo Nordisk sues Eli Lilly over ads in GLP-1 competition

Novo Nordisk alleges Eli Lilly ads do not include the most up-to-date clinical information about Lilly’s GLP-1 drugs.

Reported · Written up by our desk · M&A & Deals

Novo Nordisk has filed a lawsuit against Eli Lilly, arguing that Lilly is using advertising that is misleading in the context of GLP-1 competition.

MarketWatch reports that Novo Nordisk’s central complaint is that Lilly’s ads are not including the most up-to-date clinical information about its drugs.

The dispute underscores how aggressively GLP-1 makers are competing on marketing claims as both companies vie for market share in the obesity and diabetes drug category.

MarketWatch notes that Novo Nordisk is targeting the advertising content in the U.S., where Lilly is based.

← Newer storyPound steadies after UK fiscal rule flexibility and new chancellor

More like this

US MarketsItalian court rejects TIM's bid to block FiberCop network tariffs
US MarketsSpaceX short interest rises to about 32% of tradable float
US MarketsParamount deal challenge highlights states' push against media merger
US MarketsEagle Mountain and Nittetsu Mining expand talks on new mineral projects
US MarketsForward Air keeps share of $250 million account after customer notice

Sources

MarketWatchNovo Nordisk’s lawsuit against Eli Lilly over ads highlights intense competition in GLP-1 market
MarketWatchNovo Nordisk’s lawsuit against Eli Lilly over ads highlights intense competition in GLP-1 market

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.